Publications, Pharmaceutical

Investigating Breathable HPV-L2 Dry Powder Vaccine using GLA as Amphiphilic Lubricant and Immune-adjuvant

Dry powder respirable vaccines combine the advantage of high patient acceptability with a lack of any requirement for cold chain storage, an important logistical and economic benefit.

This paper describes a proof-of-concept validation of a dry powder human papillomavirus (HPV) respirable vaccine developed using a particle engineering approach. A key characteristic of the developed formulation is the application of glucopyranosyl lipid A (GLA) to the surface of vaccine particles to simultaneously improve aerosolization performance and recognition by the lung immune cells. Extensive in vitro characterization of the resulting formulation was carried out along with in vivo tests to determine lung deposition behavior, following intratracheal administration to mice. A subsequent short-term immunization study provided evidence of an immune response comparable to that achieved via subcutaneous delivery.

Download Publication
10 Dec 2021

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

10 May 2023

Navigating the Development for Orally Inhaled and Nasal Drug Products

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
24 Apr 2023

Navigating pMDI Reformulation 2.0

Publications, Pharmaceutical, Market Insights, Product Solutions, Sustainability, Device Innovations

Read More
19 Apr 2023

Developing More Sustainable pMDIs: A Q&A on Motivation, Progress and Challenges

Publications, Pharmaceutical, Brand Differentiation, Market Insights, Product Solutions, Sustainability

Read More
13 Mar 2023

Moving Towards Greater Recyclability in Drug Delivery – Sustainable Solutions b...

Webinars, Pharmaceutical, Sustainability, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 2 3 16
Back To Top